Highlights Adocia

Equities

ADOC

FR0011184241

Market Closed - Euronext Paris Other stock markets 11:35:07 2024-04-29 am EDT			After market 01:37:59 pm
8.36 ^EUR	-0.83%		8.37	+0.12%

Apr. 24	Adocia SA Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Mar. 22	Adocia: announces fund-raising	CF

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Adocia SA Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 24	CI
Adocia: announces fund-raising	Mar. 22	CF
Adocia Reveals Promising Preclinical Data on Adocia Islets for Cell Therapy of Diabetes	Nov. 09	CI
Adocia SA Reports Earnings Results for the Half Year Ended June 30, 2023	23-09-18	CI
Sanofi Secures EUR10 Million Exclusivity Deal for Adocia's Diabetes Drug	23-07-06	MT
Adocia Signs an Exclusivity Agreement with Sanofi for M1Pram	23-07-05	CI
Adocia SA Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-14	CI
Adocia SA Announces the Successful Phase 1 Study for Biochaperone® Lispro with Partner Tonghua Dongbao	22-12-29	CI
Adocia Sa Announces Exceptional Weight Loss for Obese People with Type 1 Diabetes Using M1pram in A Post-Hoc Analysis	22-10-06	CI
Adocia SA Reports Earnings Results for the Half Year Ended June 30, 2022	22-09-19	CI
ADOCIA Announces First Cell Therapy Preclinical Proof of Concept of AdoShell(R) Islets for the Treatment of Type 1 Diabetes	22-09-07	CI
ADOCIA Announces First Subject Treated In BioChaperone® Combo Clinical Studies with Partner Tonghua Dongbao	22-05-18	CI
Adocia Announces the First Patient Dosed in the BioChaperone® Lispro Phase 3 Program with Partner Tonghua Dongbao	22-05-09	CI
Adocia SA Reports Earnings Results for the Full Year Ended December 31, 2021	22-04-19	CI
Adocia SA Announces Start of 3 Clinical Studies for BioChaperone® Combo with Partner Tonghua Dongbao	22-04-11	CI
Adocia Files Patent for Technology to Enable Oral Drug Delivery of Peptides	21-12-13	CI
Adocia Sa Reports Earnings Results for the Half Year Ended June 30, 2021	21-09-07	CI
Adocia Initiates BC LisPram Phase 1 Clinical Trial in Pump for People with Type 1 Diabetes	21-06-29	CI
Adocia : Files Three Patents For Potential Treatment Of Metabolic Diseases	21-05-26	MT
Adocia SA Expands Clinical Development to Obesity with Patent Applications on Short-Acting Multihormonal Combinations Administered by Pumps	21-05-26	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Adocia

Equities

ADOC

FR0011184241

Highlights

Filters